ATE184196T1 - Diltiazem enthaltende arzneimittel mit verzögerter wirkstoffabgabe - Google Patents
Diltiazem enthaltende arzneimittel mit verzögerter wirkstoffabgabeInfo
- Publication number
- ATE184196T1 ATE184196T1 AT92914768T AT92914768T ATE184196T1 AT E184196 T1 ATE184196 T1 AT E184196T1 AT 92914768 T AT92914768 T AT 92914768T AT 92914768 T AT92914768 T AT 92914768T AT E184196 T1 ATE184196 T1 AT E184196T1
- Authority
- AT
- Austria
- Prior art keywords
- delayed
- products containing
- diltiazem
- medicinal products
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/721,396 US5288505A (en) | 1991-06-26 | 1991-06-26 | Extended release form of diltiazem |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE184196T1 true ATE184196T1 (de) | 1999-09-15 |
Family
ID=24897820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92914768T ATE184196T1 (de) | 1991-06-26 | 1992-06-25 | Diltiazem enthaltende arzneimittel mit verzögerter wirkstoffabgabe |
Country Status (8)
Country | Link |
---|---|
US (2) | US5288505A (de) |
EP (1) | EP0591424B1 (de) |
AT (1) | ATE184196T1 (de) |
AU (1) | AU2243092A (de) |
CA (1) | CA2111085C (de) |
DE (1) | DE69229949T2 (de) |
DK (1) | DK0591424T3 (de) |
WO (1) | WO1993000093A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US7070806B2 (en) * | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
BE1006990A5 (nl) * | 1993-04-22 | 1995-02-07 | Univ Gent | Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen. |
US20030170290A1 (en) * | 1993-06-16 | 2003-09-11 | Shug Austin L. | Delayed release carnitine |
WO1995005168A1 (en) * | 1993-08-19 | 1995-02-23 | Shug Austin L | Delayed release carnitine |
AT403988B (de) * | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
FR2742660B1 (fr) | 1995-12-22 | 1998-04-03 | Ethypharm Lab Prod Ethiques | Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US6074669A (en) * | 1997-01-20 | 2000-06-13 | Ranbaxy Laboratories Limited | Controlled drug delivery system for diltiazem |
US5914134A (en) * | 1997-01-27 | 1999-06-22 | Wockhardt Europe Limited | Process for the pulsatile delivery of diltiazem HCL and product produced thereby |
CN1127333C (zh) * | 1997-02-24 | 2003-11-12 | S.L.A.药业股份公司 | 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物 |
EP1009387B1 (de) | 1997-07-02 | 2006-04-12 | Euro-Celtique S.A. | Stabilisierte tramadol formulierungen mit verzögerter freisetzung |
US6342611B1 (en) * | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
US6524620B2 (en) * | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
US6270805B1 (en) * | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
GB9911546D0 (en) * | 1999-05-19 | 1999-07-21 | Core Technologies Limited | Release of poorly soluble agents |
DE19928312A1 (de) * | 1999-06-16 | 2000-12-21 | Schering Ag | Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe |
EP1207860B1 (de) | 1999-09-02 | 2007-10-24 | Nostrum Pharmaceuticals, Inc. | Pellet formulierung mit gesteuerter freisetzung |
US7108866B1 (en) * | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
GB0004805D0 (en) | 2000-03-01 | 2000-04-19 | Procter & Gamble | Solid bodies |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US7985420B2 (en) | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US6338857B1 (en) | 2000-05-26 | 2002-01-15 | Pharma Pass Llc | Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
US6368628B1 (en) | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
US6767899B1 (en) * | 2000-08-29 | 2004-07-27 | Leiner Health Services Corp. | Composition and method for treatment of conditions having an inflammatory component |
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
US6620439B1 (en) | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
US7858118B2 (en) * | 2001-04-11 | 2010-12-28 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
JP4704685B2 (ja) | 2002-02-21 | 2011-06-15 | バイオヴェイル ラボラトリーズ インターナショナル エスアールエル | 徐放性製剤 |
CA2496837A1 (en) * | 2002-09-09 | 2004-03-18 | Biovail Laboratories Inc. | Chronotherapeutic diltiazem formulations and the administration thereof |
WO2005016317A1 (en) * | 2003-08-19 | 2005-02-24 | Themis Laboratories Private Limited | Process for manufacture of extended release pellets containing diltiazem hci |
US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
WO2009065130A2 (en) * | 2007-11-16 | 2009-05-22 | Capricorn Pharma Inc. | Modified release formulations of diltiazem |
US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
US8173637B2 (en) * | 2008-07-24 | 2012-05-08 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
ITFI20110172A1 (it) | 2011-08-08 | 2013-02-09 | Valpharma Sa | Formulazione multiparticolata a rilascio modificato di diltiazem hcl. |
CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
WO2017062997A1 (en) | 2015-10-09 | 2017-04-13 | Reckitt Benckiser Llc | Pharmaceutical formulation |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964255A (en) * | 1972-03-13 | 1976-06-22 | Specialty Products Development Corporation | Method of inflating an automobile passenger restraint bag |
SE7813246L (sv) * | 1978-12-22 | 1980-06-23 | Haessle Ab | Fast farmaceutisk beredning innehallande kroppar med flera ytskikt |
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
JPS5845619A (ja) * | 1981-09-09 | 1983-03-16 | Hitachi Ltd | 磁気抵抗効果型薄膜磁気ヘッド |
US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4623588A (en) * | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
EP0164669B1 (de) * | 1984-06-13 | 1991-01-23 | Röhm Gmbh | Verfahren zum Überziehen von Arzneiformen |
SE8404467D0 (sv) * | 1984-09-06 | 1984-09-06 | Ferrosan Ab | Controlled-release medical preparations |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4600645A (en) * | 1985-01-31 | 1986-07-15 | Warner-Lambert Company | Process for treating dosage forms |
GB8521494D0 (en) * | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
LU86077A1 (fr) * | 1985-09-18 | 1987-04-02 | Pharlyse Sa | Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques |
LU86099A1 (fr) * | 1985-09-30 | 1987-04-02 | Pharlyse | Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant |
IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
ATE71293T1 (de) * | 1986-09-18 | 1992-01-15 | London Pharmacy Innovation | Arzneiformulierung. |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
FR2623714B1 (fr) * | 1987-11-26 | 1990-04-20 | Ethypharm Sa | Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu |
FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
FR2630647B1 (fr) * | 1988-04-27 | 1991-08-16 | Sanofi Sa | Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant |
ZA899071B (en) * | 1988-11-30 | 1990-08-29 | Schering Corp | Sustained release diltiazem formulation |
US5000962A (en) * | 1989-08-25 | 1991-03-19 | Schering Corporation | Long acting diltiazem formulation |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5175003A (en) * | 1990-04-06 | 1992-12-29 | Biosytes Usa, Inc. | Dual mechanism controlled release system for drug dosage forms |
-
1991
- 1991-06-26 US US07/721,396 patent/US5288505A/en not_active Expired - Lifetime
-
1992
- 1992-06-25 AU AU22430/92A patent/AU2243092A/en not_active Abandoned
- 1992-06-25 DE DE69229949T patent/DE69229949T2/de not_active Expired - Lifetime
- 1992-06-25 AT AT92914768T patent/ATE184196T1/de not_active IP Right Cessation
- 1992-06-25 DK DK92914768T patent/DK0591424T3/da active
- 1992-06-25 EP EP92914768A patent/EP0591424B1/de not_active Expired - Lifetime
- 1992-06-25 WO PCT/CA1992/000290 patent/WO1993000093A1/en active IP Right Grant
- 1992-06-25 CA CA002111085A patent/CA2111085C/en not_active Expired - Lifetime
-
1994
- 1994-09-23 US US08/311,722 patent/US5529791A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0591424B1 (de) | 1999-09-08 |
CA2111085A1 (en) | 1993-01-07 |
DE69229949T2 (de) | 2000-03-09 |
US5529791A (en) | 1996-06-25 |
WO1993000093A1 (en) | 1993-01-07 |
US5288505A (en) | 1994-02-22 |
CA2111085C (en) | 1999-04-27 |
DK0591424T3 (da) | 1999-12-20 |
EP0591424A1 (de) | 1994-04-13 |
DE69229949D1 (de) | 1999-10-14 |
AU2243092A (en) | 1993-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE184196T1 (de) | Diltiazem enthaltende arzneimittel mit verzögerter wirkstoffabgabe | |
SE7906119L (sv) | Lekemedel-retardform med olosliga porosa diffusionsholjen | |
DK156289A (da) | Farmaceutisk praeparat indrettet til kontrolleret afgivelse af aktiv bestanddel | |
GR1002564B (el) | Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως. | |
ES2094539T3 (es) | Preparacion farmaceutica y procedimiento para su preparacion. | |
FI950319A0 (fi) | Säädellyn vapautumisnopeuden omaava morfiinivalmiste | |
NO891680L (no) | Osmotisk kontinuerlig avgivende oralt avgivelsessystem inneholdende et farmasoeytisk akseptabelt aktivt middel som har forbedrede kjernemembran-adhesjonsegenskaper. | |
IE883810L (en) | Sustained release pharmaceutical compositions | |
CA2376226A1 (en) | New formulation | |
MX9704910A (es) | Formula de liberacion controlada (albuterol). | |
NZ230470A (en) | Controlled release device coated with one or more asymmetric membranes, and preparation thereof | |
EP0160501A3 (de) | Intranasale Zusammenstellung mit verzögerter Freigabe und Gebrauchsanweisung | |
IE882898L (en) | Solubility modulated drug delivery device | |
DE60042972D1 (de) | Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung | |
HUT75029A (en) | Systems for controlled release of pilocarpine, and semipermeable capsule containing the active ingredient | |
DK0540813T3 (da) | Acetazolamid-præparat med vedvarende afgift af aktivt stof | |
NO950950L (no) | Farmasöytisk preparat | |
AU7817891A (en) | Pharmaceuaticals with delayed release of active agent | |
MY103853A (en) | Controlled release pharmaceutical preparation and method for producing the same. | |
EP0509098A4 (en) | Ataractic | |
ITBO930460A0 (it) | Procedimento per preparare forme farmaceutiche a rilascio controllato del principio attivo e le forme farmaceutiche cosi' ottenute. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |